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Viable Alternative to Surgery
or Just Another Short-Term Fix*
John R. Laird, MD
Sacramento, California
Femoral endarterectomy with patch angioplasty has long
been the favored approach to the treatment of patients with
symptomatic common femoral artery (CFA) occlusive dis-
ease. The procedure can be performed through a small
incision, and the plaque can often be removed en bloc,
followed by enlargement of the CFA and ostia of the
superficial femoral artery and profunda femoris with a patch.
In skilled hands, this operation can be performed with low
morbidity and mortality and with a short hospital stay.
See page 792
Primary patency rates of 74% to 91% at 5 years have been
reported in the literature (1–5). Italian investigators recently
reported their experience with 121 CFA endarterectomies
in 117 patients (6). All procedures were performed under
regional anesthesia with no perioperative deaths or major
complications. Minor complications occurred in 6.6% of
cases. At 7 years, the primary and primary assisted patency
rates were 96% and 100%, respectively. Femoral endarter-
ectomy can also be performed in conjunction with iliac
stenting as an alternative to the traditional surgical approach
of aortobifemoral bypass grafting. This “hybrid” approach to
iliofemoral disease has gained greater acceptance because of
the favorable long-term results and decreased morbidity
compared with aortobifemoral bypass (7–10). Although
major complications following CFA endarterectomy are
infrequent, minor complications have been reported in 6.6%
to 9% of cases (1,6). In one series, a wound infection rate of
14% was seen (11).
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other hand, has been regarded as a less effective treatment
strategy for CFA stenosis/occlusion. The plaque in the
CFA is often bulky, eccentric, and heavily calcified and may
not respond well to balloon dilation. There is frequently
involvement of the femoral bifurcation, with the potential
for plaque shift into the profunda femoris or superficial
femoral artery. The prevailing viewpoint is also that stent
implantation into the CFA should be avoided if at all
possible. Although data regarding CFA stenting are limited,
there is the perception that stenting may complicate or limit
future surgical options and that stents have a higher failure
rate in this location. In addition, there is the concern that
stenting across the origin of the profunda femoris could
potentially lead to future compromise of this critically
important source of collaterals to the lower extremity. Only
a few small series of CFA PTA and stenting have been
reported. Silva et al. (12) reported 21 CFA procedures in 20
patients. Procedural success was achieved in 90% of cases.
At a mean follow-up of 11.4 months, 89% of patients
continued to show improvement by at least 1 Rutherford
category. Stricker and Jacomella (13) reported on 33 stent-
assisted angioplasty procedures of the CFA and bifurcation
in 27 patients. Technical success was 100%. At 3 years, the
cumulative patency rate was 83%.
In this issue of the Journal, Bonvini et al. (14) challenge
the current dogma regarding treatment of the CFA. They
present a large, retrospective, single-center experience with
CFA PTA. Using a prospectively maintained database, they
described the outcomes of 360 consecutive percutaneous
interventions for CFA atherosclerotic disease. This is the
largest series of its kind regarding open or endovascular
treatment of the CFA. The majority of the CFA interven-
tions (73.1%) were done in conjunction with treatment of
inflow and outflow vessels. Balloon angioplasty was the
primary mode of therapy in almost all cases. CFA stenting
was performed in 133 cases (36.9%) because of a suboptimal
angioplasty result. A small number of excisional atherec-
tomy procedures (6.9%) were performed in the later years of
this series. The overall procedural success rate was 92.8%,
with a low rate of major complications. One-year follow-up
was available for 87.2% of patients, with a duplex ultra-
sound–derived binary restenosis rate of 27.6%. The clini-
cally driven target lesion revascularization rate (TLR) was
19.9%. Interestingly, binary restenosis and the need for
TLR were lower for those patients who received stents.
There was also a trend toward better clinical outcomes for
the small number of patients who underwent excisional
atherectomy.
Are the results from this study good enough to change
the current treatment paradigm for CFA disease? First, a
number of study limitations must be addressed. Although
the 1-year results are quite acceptable, the longer-term
outcomes are not as promising. The investigators reported
that “restenoses 50% observed beyond 18 months were
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and were excluded from the outcome analysis” (14) This is
an artificial distinction that would have little meaning to the
patient who returns after 2 years with recurrent symptoms
due to renarrowing or reocclusion of the CFA. In addition,
this method of outcomes reporting is not consistent with the
reporting standards for outcomes following open or endo-
vascular revascularization procedures. Review of the
Kaplan-Meier curves for restenosis and TLR revealed a
significant drop-off in patency after 1 year, with frequent
need for reintervention. The 5-year primary patency rate
appeared to be only approximately 50%. These longer-term
results are inferior to those achieved with endarterectomy
and patch angioplasty. Although a large number of stents
were implanted in the CFA in this series with improved
outcomes compared with PTA alone, systematic radio-
graphic follow-up of these stents to evaluate for stent
fracture was not performed. The rate and implications of
stent fracture in this location are unknown. It also remains
unclear as to whether CFA stenting, as performed in this
series, would complicate future surgical approaches to CFA
disease if symptomatic restenosis should occur.
The researchers correctly pointed out that the techniques
employed in this study are not contemporary and that the
results achieved may not reflect outcomes that could be
achieved in current practice. In Europe, where drug-eluting
balloons and drug-eluting stents are commercially available,
the percutaneous approach to CFA may be entirely differ-
ent. In the United States, excisional atherectomy or other
debulking modalities are commonly employed for CFA
disease (15). It remains uncertain how outcomes following
use of these treatment approaches would compare with
those of surgical outcomes or balloon angioplasty alone.
The investigators are to be congratulated for adding
significantly to our knowledge regarding the endovascular
treatment of CFA disease. They demonstrated that excel-
lent short-term results can be achieved with balloon angio-
plasty and provisional stent implantation. These results
highlight, however, that balloon angioplasty alone with or
without stent implantation is not ready to replace surgery as
the “gold standard” treatment for CFA occlusive disease. A
demonstration of better long-term patency with newer
endovascular modalities will be necessary for that to occur.
Local drug delivery, with or without lesion debulking, offersthe promise of improved outcomes; however, further study
is required.
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